iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Source: GlobeNewswire· iBio, Inc.· August 4, 2026
SynaBot summary
Biotech firm iBio has appointed endocrinologist Molly Carr as its new Chief Medical Officer. Carr's expertise in metabolic diseases will guide the development of iBio's antibody therapies targeting obesity and related conditions.
Key takeaways
- Biotech company iBio names endocrinologist as Chief Medical Officer
- Focus on developing antibody therapies for metabolic diseases
- Expertise in obesity and cardiometabolic conditions is key
- Reinforces clinical leadership in AI-assisted drug discovery
Why it matters
This appointment signals a strategic focus on specialized medical expertise within AI-driven drug development. For AI users in healthcare, it highlights the increasing integration of deep clinical knowledge with advanced therapeutic research.
This story was reported by GlobeNewswire. Read the full original article:
Read on GlobeNewswire 
